| 6805 wileyonlinelibrary.com/journal/jcmm 1 | INTRODUC TI ON Extracellular vesicles (EV) such as exosomes and microvesicles are bi-lipid membranous vesicles with endocytic origin that are released by many cell types including immune, endothelial and mesenchymal stem cells, erythrocytes and platelets. 1 EV participate in intercellular communication by carrying and delivering cargo including proteins, lipids, miRNA and mRNA specific to the type of cell from which they originate. 2 EV are key mediators of a process now thought to be a form of intercellular signalling that impacts the physiology of cells, tissues and organs. 3 EV are released constitutively or after stimulation and taken up by other cells via membrane fusion or ligand-receptor interactions. 4 Due to their ability to trap their cargo and circulate freely in body fluids, EV are natural sources of non-invasive diagnostic and prognostic biomarkers that may also be used as vehicles of targeted therapy for tumour progression, neurodegeneration, autoimmune Abstract Extracellular vesicles (EV) can transfer cellular molecules for specific intercellular communication with potential relevance in pathological conditions. We searched for the presence in plasma from coronary artery disease (CAD) patients of EV containing the adenosine A 2A receptor (A 2A R), a signalling receptor associated with myocardial ischaemia and whose expression is related to homocysteine (HCy) metabolism. Using protein organic solvent precipitation for plasma EV preparation and Western blot-How to cite this article: Ruf J, Vairo D, Paganelli F, Guieu R. Extracellular vesicles with ubiquitinated adenosine A 2A receptor in plasma of patients with coronary artery disease. J Cell Mol Med. 2019;23:6805-6811. https ://doi.
ting for protein identification, we found that plasma from CAD patients contained various amounts of EV with ubiquitin bound to A 2A R. Interestingly, the presence of ubiquitinated A 2A R in EV from patients was dependent on hyperhomocysteinemia, the amount being inversely proportional to A 2A R expression in peripheral mononuclear cells in patients with the highest levels of HCy. CEM, a human T cell line, was also found to released EV containing various amounts of ubiquitinated A 2A R in stimulated conditions depending on the hypoxic status and HCy level of culture medium.
Together, these data show that ubiquitinated A 2A R-containing EV circulate in the plasma of CAD patients and that this presence is related to hyperhomocysteinemia.
A 2A R in plasma EV could be a useful tool for diagnosis and a promising drug for the treatment of CAD.
K E Y W O R D S
adenosine A 2A receptor, coronary artery disease, extracellular vesicles, homocysteine, ubiquitin disorders and other human diseases. 5 In cardiovascular disease, EV represent one of the most intensely studied and rapidly growing areas of research. 6, 7 EV were shown to exert diverse and sometimes discordant biological effects in different studies related to cardiovascular disease. For example, EV can play an atheroprotective or atherogenic role in several conditions accompanying atherosclerosis. 8 Adenosine greatly impacts the cardiovascular system via four specific G protein-coupled receptors, named respectively A 1 , A 2A , A 2B and A 3 . Among them, the A 2A receptor (A 2A R) is strongly expressed in coronary cells and its activation increases coronary blood flow, 9 partly through the production of cAMP in target cells. 10 A 2A R from patients with coronary artery disease (CAD) is poorly expressed and, consequently, produces low level of cAMP, two characteristics that are associated with myocardial ischaemia, as documented by positive exercise stress testing or reduced flow reserve. [11] [12] [13] The down-regulation of A 2A R expression in CAD patients is related to the homocysteine (HCy) metabolism via its degradation product H 2 S. 14 Circulating EV can be considered as a reserve of functional G protein-coupled receptors as previously suggested from data obtained on a mouse model of heart cellular stress for angiotensin II type 1 receptor. 16 Taking into account the major role of A 2A R in cardiovascular disease and the potential contribution of circulating EV in delivering cell receptor from donor to target cells, we searched for the presence of A 2A R in EV from plasma of patients with CAD and culture supernatant of human lymphoblastoid T cells cultured in CAD-like conditions.
| MATERIAL S AND ME THODS

| Human materials
Fourteen patients (11 men and three women, 56-58 years old) with angiographically documented CAD were included in this pilot study ( Table 1 ). The first group consisted of eight patients selected blind and the second group was six patients with moderate hyperhomocysteinemia. Controls were eight healthy individuals (six men and two women, 56-64 years old) with a normal level of HCy (Table 1) recruited from the research laboratory or hospital staff, without medical treatment or history of cardiovascular disease. The study was conducted in compliance with the principles of the Declaration of Helsinki and approved by the Ethics Committee for Human
Research of our University Hospital. All participants provided written informed consent to participate.
Plasma and PBMC were obtained from blood collected by venipuncture at the brachial vein in citrate tube and cell preparation tube (CTP) for the separation of mononuclear cells (Vacutainer, Becton-Dickinson), respectively, according to the manufacturer's instructions.
Extracellular vesicles were isolated from fresh plasma by a simple, rapid and reliable solvent-based protein precipitation method as previously described. 17 Briefly, 200 µL of plasma was mixed with 800 µL cold acetone (−20°C) in 1.5 mL conical tube and centrifuged at 3000 × g for 1 minute. After centrifugation, 500 µL of EV-containing supernatant was freeze at −20°C and dried in a Savant SpeedVac concentrator (Thermo Fisher Scientific).
Extracellular vesicles and PBMC were analysed by Western blotting as previously reported. [11] [12] [13] [14] [15] Briefly, freeze-dried EV corresponding to 100 µL of plasma and cell pellets corresponding to 0.25 × 10 6 PBMC were solubilized in 15 µL Laemmli sample buffer (BioRad) with 5% SDS, 5% 2-mercaptoethanol and a complete set of protease inhibitors (Roche), heated for 5 minutes at 95°C and loaded on 12% SDS-PAGE minigel (BioRad). Prestained molecular weight markers (BioRad) have always been loaded onto the gel. After electrophoresis, separated proteins were blotted onto nitrocellulose membrane.
Protein detection was conducted using an appropriate primary antibody: anti-CD63 and anti-CD9 (EXOAB-KIT, Ozyme), anti-ubiquitin (clone 6C1, Sigma-Aldrich) and anti-A 2A R (Adonis, 18 CliniSciences).
Blots were then revealed using phosphatase alkaline-labelled and plots of pick profiles were generated. Lines were drawn to select the peaks of interest, and the peak areas were integrated and converted into pixel intensities. Results were given as per cent of total pixels of all the relevant bands on a same migration line on the blot.
The protein load was controlled by the reproducibility of the results,
Western blots being done in triplicate.
| Homocysteine assay
Total HCy from the human plasma was quantified with the liquid chromatography-tandem mass spectrometry Clinmass ® apparatus using the dedicated kit (Homocysteine in plasma/serum, Recipe) according to the manufacturer's instructions. Results (in µmol/L) are the mean ± SD of duplicates.
| CEM T cell line
CEM, a human lymphoblastoid T cell line 19 with 5% SDS, 5% 2-mercaptoethanol and a complete set of protease inhibitors (Roche) and heated for 5 minutes at 95°C. EV from culture supernatant and CEM T cells were analysed by Western blotting as described above for the human material.
Cell viability was monitored using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay as previously described. 14 MTT (0.5 mg in 100 µL of PBS, pH 7.3) was added to 24-well plates containing 0.5 × 10 6 cells/mL cultured in the three conditions (Control, Hypoxia, Hypoxia + HCy) 3 hours prior to the end of the 24 hours incubation period. After treatment, cells were pelleted (10 000 × g for 5 minutes) and supernatants were discarded.
The insoluble violet formazan crystals associated with the cell pellets were dissolved into pure dimethyl sulfoxide and absorbance was measured at 550 nm. Results are the mean ± SD of duplicates.
| RE SULTS
| Presence of ubiquitinated A 2A R in EV of CAD patients
First, we tested plasma from four patients with CAD (Reference Numbers 1, 4, 6 and 7) for the presence of EV carrying A 2A R. EV were isolated from plasma using acetone to remove proteins by precipitation leaving purified EV suspended in the liquid phase. 17 Freeze-dried EV were submitted to Western blot procedure using Adonis, a monoclonal antibody to the human A 2A R 18 widely used in previous studies [11] [12] [13] [14] [15] and anti-tetraspanin CD9 as a biomarker of EV with a low molecular weight (28 kD) migrating at high distance from the A 2A R to test both in same lanes of gel. Intriguingly, we found using Adonis various amounts of a band (intensity from 0% to 68.5% pixels depending of the patient) that migrated to a higher position than expected (45 kD for cellular A 2A R) between the 75 and 50 kD markers in three to four patients ( Figure 1A) . We found CD9 bands displaying similar intensities (from 3.3% to 64.0% pixels) to those obtained for the A 2A R. The negative patient for A 2A R probably contained a low level of receptors, which corresponded to a low level of EV in plasma as judged by the faint intensity of the CD9 band (3.3% pixels) and consequently had undetectable A 2A R in our experimental conditions ( Figure 1A ).
Next, we performed another set of Western blots using preparations of EV from the same four plasma samples. The use of a different anti-tetraspanin marker CD63 (mol wt of 53 kD) gave a band intensity gradation similar to that obtained with CD9 and confirmed that the plasma level of A 2A R in CAD patients was related to their EV content ranking patients from lowest to highest as follows: Reference Numbers 7,1, 4 and 6 ( Figure 1B) . Looking for a plausible post-translational process that could have increased the molecular weight of the A 2A R in the context of EV trafficking we used an anti-ubiquitin antibody, which revealed the same heavy A 2A R bands as Adonis with a similar intensity gradation between patients, as previously described ( Figure 1B ). Blotted bands of ubiquitinated A 2A R migrated above the CD63 bands. Together, these data suggested that exosomal A 2A R contained at least two molecules of ubiquitin (mol wt 8 kD) raising the molecular weight of A 2A R from 45 to 61 kD. PBMC, Western blots were made in triplicates, each giving a similar result. Densitometric quantification of representative blots was performed and expressed as % of total pixels (Figure 2A) .
| Comparison of EV and cell expression of A 2A R
Intensity of the patient bands varied from 0% to 26 (Table 1) .
We then confirmed the presence of heavy A 2A R (61 kD) in EV released by stimulated CEM T cells in culture medium and prepared using a commercial kit ( Figure 2B ). Western blots were performed as above using EV from 10 mL of culture supernatant and 0.25 × 10 6 
CEM T cells. Maximal release of A
| Relationship between A 2A R export in EV and hyperhomocysteinemia
Finally, to further explore the relationship between the A 2A R export via EV and hyperhomocysteinemia, we compared on a same blot the A 2A R content of the EV from 6 healthy individuals (Reference Letters C-H) with normal level of HCy taken as controls with that of 6 CAD patients (Reference Numbers 9-14) with moderate hyperhomocysteinemia (Table1). The results shown in Figure 3 confirmed the previous data. The control samples lacked A 2A R, but those from CAD patients with moderate hyperhomocysteinemia all expressed the A 2A R band of a pixels intensity of 6.6 to 40.4% ( Figure 3A) . The scatter plot in Figure 3B shows the relationship between A 2A R levels in EV of CAD patients and their HCy levels greater than 20 µmol/L. The patients 10, 12 and 14 with the lowest HCy levels gave the A 2A R bands with the lowest intensities and the patients 9, 11 and 13 with the highest HCy levels had the most A 2A R in their EV.
| D ISCUSS I ON
We report here for the first time the presence of ubiquitinated A 2A R in EV isolated from plasma of CAD patients. Ubiquitinated A 2A R were also found in EV released in the culture supernatant of a stimulated human T cell line.
Plasma contains a mix of EV with different sizes derived from many different cells in varying proportions. Sorting of many membrane proteins into EV coincides with their association with tetraspanin membrane proteins. 20 We found that A 2A R expression in EV was related to a similar expression of EV assessed by CD9 and CD63 tetraspanins.
We also found here that A 2A R in EV was ubiquitinated. Ubiquitin is a highly conserved 76 amino acid polypeptide that is covalently attached to substrate proteins via a lysine residue. Ubiquitination is a reversible modification and ubiquitin moieties can be removed from the substrate protein by a family of deubiquitinating enzymes. 21 G protein-coupled receptors that undergo agonist-induced ubiquitination are usually internalized and targeted for degradation in lysosomes. However, after deubiquitination they can be redirected to the resensitization pathway and recycled back to the cell surface. 22 The addition of a single ubiquitin to a substrate is defined as monoubiquitination and is implicated in various functions including endocytosis of plasma membrane proteins and sorting of proteins to the multivesicular body. 23 Moreover, several lysine residues in the substrate can be tagged with single ubiquitin molecules, giving rise to multiple monoubiquitination. 24 Here, the ubiquitinated A 2A R migrated in SDS-PAGE to approximately 61 kD suggesting that it contained at least two molecules of ubiquitin. Given the presence of two potential ubiquitination sites on lysine residues 315 and 391 in the acting on the mitogen-activated protein kinase pathways 26, 27 and cell signalling can be related to endocytosis and endosomal trafficking. 28 We therefore assume that HCy could act on the ubiquitination process so that A 2A R do not undergo proteosomal degradation but are exported into exosomes. In this case, hyperhomocysteinemia would favour the salvage pathway described above.
Exosomes contain ubiquitinated proteins that can serve as markers of exosomes 29 and ubiquitin plays a major role in the endosomal trafficking leading to exosomal release. 30 Otherwise, ubiquitination controls cell surface expression of MHC class II molecules in dendritic cells 31 and the ubiquitin-specific protease USP4 was reported to regulate the cell surface level of the A 2A R in HEK293 transfected cells. 32 Multiple monoubiquitins could confer resistance to the action of deubiquitinating enzymes that would otherwise result in rapid elimination of a single ubiquitin, thereby promoting receptor recycling. 33 Given all these considerations, the putative presence here of bi-monoubiq- 
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